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Abstract
Background: Ghrelin may influence the development of obesity through its role in the control of energy balance, food
intake, and regulation of body weight. The effects of ghrelin are mediated via the growth hormone secretagogue receptor
(GHSR).
Methodology/Principal Findings: We genotyped 7 single nucleotide polymorphisms (SNPs) in the GHSR gene and assessed
the association between those SNPs and obesity and type 2 diabetes-related phenotypes from 507 middle-aged overweight
persons with impaired glucose tolerance participating in the Finnish Diabetes Prevention Study (DPS). Additionally, we
performed in silico screening of the 59-regulatory region of GHSR and evaluated SNPs disrupting putative transcription
factor (TF) binding sites in vitro with gelshift assays to determine differences in protein binding between different alleles of
SNPs. Rs9819506 in the promoter region of GHSR was associated with body weight (p=0.036); persons with rs9819506-AA
genotype having the lowest body weight. Individuals with rs490683-CC genotype displayed highest weight loss in the
whole study population (p=0.032). The false discovery rate for these results was ,10%. Rs490683 and rs509035 were
associated with several measures of glucose and insulin metabolism during the follow-up. Rs490683 may be a functional
SNP, since gelshift experiments showed differential protein binding between the alleles, with higher binding to the G-allele.
Rs490683-C may disrupt a putative binding site for the TF nuclear factor 1 (NF-1), thus rs4906863-GG genotype where the
NF-1 site is intact may lead to a higher GHSR gene expression.
Conclusion/Significance: Polymorphisms in the GHSR promoter may modify changes in body weight during long-term
lifestyle intervention and affect ghrelin receptor signalling through modulation of GHSR gene expression.
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Introduction
Ghrelin is predominantly produced by the stomach and is the
only known orexigenic hormone and endogenous ligand for the
growth-hormone-secretagogue receptor (GHSR) [1,2]. Ghrelin is
composed of 28 amino acids and is uniquely modified by the
addition of an octanoyl group to the serine residue at position
three. This acylation is necessary for ghrelin to bind to the GHSR
and to cross the blood-brain barrier [3].
Ghrelin is implicated in growth hormone release [2], energy
balance [4], food intake, and long-term regulation of body weight
[5,6]. A major target for ghrelin is the arcuate nucleus of the
hypothalamus, where ghrelin acts on appetite-stimulating groups of
neurons, which express the potent orexigenic neuropeptides
neuropeptide Y (NPY) and agouti-related protein (AGRP) [7]. These
NPY/AGRP-containing neurons also express ghrelin receptors [8].
The GHSR gene, located on chromosome 3q26.31, encodes a
protein that belongs to the family of G protein-coupled receptors
[9]. Two distinct GHSR transcripts are known: GHSR type 1a acts
as ghrelin receptor, whereas type 1b is a truncated form of the
GHSR 1a and pharmacologically inactive [9]. GHSR 1a is
expressed mainly in the hypothalamus and pituitary [10,11],
whereas the GHSR type 1b mRNA expression has also been
found in many peripheral organs [10], including immune cells
[12,13], indicating that ghrelin may have multiple functions in
these tissues but with thus far unknown importance.
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homeostasis-related phenotypes. GHSR-deficient mice show resis-
tance to diet-induced obesity when supplied with a high-fat diet
early in life, which implicates that functional ghrelin signalling is
required for the full development of diet-induced obesity [1,14].
In humans, the GHSR gene lies within a quantitative trait locus
strongly linked to multiple phenotypes related to obesity and the
metabolic syndrome [15]. Baessler et al. have described a
‘‘susceptible’’ and ‘‘non-susceptible’’ haplotype for obesity of five
GHSR single nucleotide polymorphisms (SNPs) [15]. Vartiainen et
al. [16] showed an association between insulin values and a GHSR
variant. A recent study reports a weak association between one
GHSR variant and BMI [17]. In recently conducted genome-wide
association (GWA) studies, GHSR was not among the few genes
associated with obesity [18,19] or type 2 diabetes [20,21]. Although
GWAstudies arevery elegantly conductedto unravel thegenetics of
chronic diseases, candidate gene analyses also can often contribute
to ourknowledgeabout these disorders. Thus, we investigatedSNPs
in the GHSR gene and their association with obesity, glucose and
insulin metabolism, and the conversion from impaired glucose
tolerance (IGT) to type 2 diabetes in participants of the Finnish
Diabetes Prevention Study (DPS). We demonstrated an association
between one GHSR promoter SNP and weight loss during a 3-year
follow-up and consequently showed that this SNP might have
functional consequences on the expression of the GHSR gene.
Results
We genotyped 7 SNPs in the GHSR gene, four of which are
located in the 59-region, one in exon 1, one intronic and one SNP
in the 39-region (Fig. 1A). Rs490683, which was associated with
weight loss and measures of glucose metabolism, is in strong
linkage disequilibrium (LD) with rs509035 (Fig. 1B).
Association with obesity-related phenotypes
At baseline, no significant differences were observed between the
genotypes of all seven SNPs for obesity-related traits (Table 1 for
rs490683,data not shown forother SNPs).However, usingrepeated
measures ANOVA we observed that during the 3-year follow-up
weight was significantly different between genotypes of rs9819506
(Fig. 2A) and tended to differ for BMI (p/q=0.056/0.041).
During the 3-year intervention. all subjects being analyzed
together, individuals with rs490683-CC genotype lost significantly
more weight than others (Fig. 2B). When the two intervention groups
were analyzed separately, differences in weight loss according to the
genotypes were only observed in the intervention group (Fig. 2B).
No significant differences in weight loss during the intervention
period were observed for other SNPs (data not shown).
We carried out haplotype analysis with the 4 genotyped SNPs in
haploblock 1 (rs6772676, rs474225, rs490683 and rs9819506,
respectively; Fig. 1A). The haplotype analysis did not offer more
information than the single SNP analysis, thus these results were
not included in the current manuscript. Concerning weight, the G-
allele of rs9819506 seems to be responsible for higher weight in all
subjects. The haplotype analysis regarding weight change did not
reveal any significant results, largely due to the fact that not all
relevant haplotypes could be tested due to their low frequency
(data not shown).
Association with phenotypes related to glucose
metabolism
At baseline, no significant associations with measures of glucose
metabolism and the seven genotyped GHSR polymorphisms were
observed (Table 1 for rs490683, data not shown for other SNPs).
Differences between genotypes were observed with the
rs6772676 SNP for fasting (p/q=0.038/0.035) and 2-h plasma
glucose (p/q=0.006/0.035), with heterozygotes having the
highest levels in the whole study population when data were
analyzed longitudinally. In similar analysis for rs490683, 2-h
plasma glucose (Fig. 3A) and 2-h serum insulin levels (p/
q=0.050/0.041) differed significantly according to different
genotypes with rs490683-CC subjects tending to have the lowest
2-h glucose and insulin levels throughout the follow-up. Three-
year changes in fasting plasma glucose, 2-h plasma glucose and 2-h
serum insulin in the entire study population differed between
rs490683 genotypes (Fig. 3B, C and E, respectively). When the
study groups were analyzed separately, significant differences were
found between the rs490683 genotypes in fasting and 2-h plasma
glucose and fasting and 2-h serum insulin (Fig. 3B–E) in the
control group, but not in the intervention group. Levels of glucose
and insulin decreased in persons with rs490683-CC genotype
during the follow-up. Furthermore, differences between genotypes
were also observed with the rs509035 SNP for 2-h plasma glucose
and fasting insulin in the whole study population when data were
analyzed longitudinally (p/q=0.014/0.035 and p/q=0.037/
0.035, respectively). Changes in parameters of glucose metabolism
differed according to rs509035 in the whole study population
(fasting plasma glucose: p/q=0.046/0.086, 2-h plasma glucose:
p/q=0.011/0.069, 2-h serum insulin: p/q=0.037/0.086) and in
the control group separately (2-h plasma glucose: p/q=0.038/
0.267, 2-h serum insulin: p/q=0.014/0.152), with persons with
rs509035-TT genotype showing a decrease in those parameters
during the follow-up.
None of the GHSR polymorphisms were statistically significantly
associated with risk of type 2 diabetes (data not shown).
Differential protein binding in the 59-regulatory region
We used the Genomatix MatInspector software [22] to identify
putative transcription factor (TF)-binding sites in the 59-region
(haploblock 1) of the GHSR gene that may be implicated in the
regulation of the gene expression. We screened 20 kb upstream of
the translation initiation site and identified 8 SNPs that potentially
disrupted one or more TF-binding sites in either one of the alleles
or both. Subsequently, we tested oligonucleotides containing either
of the alleles of each SNP (supplementary Table S1) to identify
possible differences in protein binding between the alleles of each
SNP in gelshift assays using rat hypothalami as a TF protein
source. The SNPs rs6772676 and rs490683 showed different
protein binding when both alleles were compared (Fig. 4).
Specifically, when the protein binding of the ‘‘wild-type’’ allele
was normalized to 100%, rs6772676-T allele showed lower protein
binding (only 28%) compared to the rs6772676-C allele.
Furthermore, rs490683-G allele showed higher protein binding
(745%) compared to that of the rs490683-C allele. The G-allele of
rs490683 is present in the core sequence of the putative binding
site of the TF nuclear factor 1 (NF-1), which is disrupted when G is
replaced by C (Table 2).
Discussion
We have shown that two SNPs (rs490683 and rs9819506) in the
promoter region of the human GHSR gene are associated with the
change in body weight and BMI. The GHSR SNP rs9819506,
which has not been examined in previous studies, showed an
association and individuals with rs9819506-AA genotype showed
lowest values for body weight and a trend for lowest BMI during a
3-year follow-up. Interestingly, subjects with rs490683-CC geno-
type displayed highest weight loss in the whole study group as well
GHSR SNPs and Obesity
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Baessler et al. [15] showed an association between GHSR
haplotypes and obesity. The so-called ‘‘susceptible’’ haplotype
tested in that study was found more often in obese individuals and
included rs490683-C and rs509035-T alleles. These results might
be considered contradictory to ours, where we see the rs490683-
CC genotype as ‘‘beneficial’’ genotype. However, it is difficult to
compare data from a longitudinal intervention study with
individuals at high risk of type 2 diabetes describing the effect of
the certain genotype on the weight development and a cross-
sectional study carried out in a different population. A more recent
study, however, could not point out a clear relationship between
GHSR SNPs and obesity [17]. Wang et al. [23] showed that obese
children and adolescents had a higher rs495225-T allele frequency
than underweight subjects, but this trend could not be confirmed
in their further studies. Thus, they concluded that there is no
Figure 1. The human GHSR gene and location of SNPs and their LD measures. A. Schematic representation of the human GHSR gene
indicating the locations of analyzed single nucleotide polymorphisms (SNPs) that belong to two haploblocks. (black star), SNPs genotyped in the
Finnish Diabetes Prevention Study population. # SNPs from HapMap database in transcription factor (TF) binding sites and tested in gelshift assays.
B. Standardized pair-wise linkage disequilibria (LD) measures of D’ and r
2 for seven GHSR single nucleotide polymorphisms (SNPs) of the Finnish
Diabetes Prevention Study. Major/minor alleles and the minor allele frequency (in parentheses) are included below each SNP identification number.
For each cell, the number on the top line is D’ and the number on the bottom line is r
2. Strength of LD is indicated in greyscale with black denoting
strong and white weak LD.
doi:10.1371/journal.pone.0002941.g001
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regulation. In our study, SNPs rs495225 and rs565105 were not
unequivocally associated with measures of obesity or type 2
diabetes.
Vartiainen et al. [16] showed that subjects with rs495225-CC
genotype had highest area under the insulin curve values and
IGFBP-1 concentrations. In the present study, in the DPS
population rs6772767, rs490683 and rs509035 were associated
with several measures of glucose metabolism over four consecutive
measurements. Beneficial changes in glucose metabolism could be
observed specifically in individuals with rs490683-CC and
rs509035-TT genotypes, especially in the control group. The
control group in the DPS trial can be considered as a prospective
cohort of people at high risk of diabetes. Since changes in
measures of glucose metabolism during the study period were only
observed in the control group, it indicates that the rs490683-CC
genotype and the rs509035-TT genotype are beneficial or
protective genotypes. A reduction in body weight was, however,
evident when the whole study population was analysed, but this
was mostly explained by the change in the intervention group.
This finding is in some discrepancy with the association shown
with measures of glucose metabolism. Thus, it might be that the
different association with body weight and glucose metabolism are
mediated via different mechanisms. In addition, we cannot
exclude the impact of the moderate population size contributing
to these varying associations. Unfortunately, we do not have the
possibility to increase the size of the DPS population, but hopefully
in the future it is possible to carry out joint analyses with the data
from several other similar type of lifestyle intervention studies.
However, we feel that the nature of DPS, as being a longitudinal
study with an intensive lifestyle intervention in a carefully
phenotyped high risk population, is unique and therefore our
results offer valuable contribution and addition to the knowledge
about weight and glucose control.
Rs490683 and rs509035 are in strong LD with each other and
this may further explain the similar results concerning glucose
metabolism phenotypes. Rs509035 is located in the intron of the
GHSR gene, thus it was not included in our analysis for putative
TF binding sites. Nevertheless, it cannot be excluded that this SNP
has functional consequences, but we did not test this. Thus, based
on our results we may speculate that rs490683 could be the causal
SNP accounting for the effects observed.
As a limitation we need to point out that due to the distribution
of these data, only non-parametric tests could be carried out where
adjustments for covariates were not possible. To account for
multiple testing and to control false positive rate, or type I error,
we calculated the false discovery rate (FDR), expressed as q-value,
for given p-values. Associations with a significant p-value, but a
high q-value must be cautiously interpreted.
To test the potential functional relevance of SNPs in the 59-
region of GHSR we first examined the regions where SNPs are
possibly disrupting putative TF-binding sites with in silico promoter
analysis. We then tested oligonucleotides with each allele of each
SNP in gelshift assays using nuclear protein extracts from rat
hypothalamus. We chose to use hypothalami of male rats as a
comparable protein source, due to the fact that this tissue is
unavailable from a human source. The DNA sequences (oligos)
used for the gelshift experiments were designed to match the
human sequence. We observed that nuclear proteins were binding
to the sequence containing the rs490683-G allele with much higher
Table 1. Baseline characteristics of the DPS study subjects according to the rs490683 polymorphism of the GHSR gene.
Genotype P-value
*
rs490683-CC (n) rs490683-CG (n) rs490683-GG (n)
Sex (M/F) 13/33 (46) 68/147 (215) 85/161 (246) 0.635
b
Age (years) 5467 (46) 5667 (215) 5567 (246) 0.246
c
Weight (kg) 88.5613.8 (46) 84.4612.9 (215) 87.4615.2 (246) 0.080
a
BMI (kg/m
2)3 2 . 4 64.9 (46) 30.864.2 (215) 31.464.7 (246) 0.132
a
Waist circumference (cm) 101.5610.2 (46) 100.7610.8 (213) 101.6611.3 (246) 0.062
Waist-to-hip ratio 0.9160.07 (46) 0.9260.07 (213) 0.9260.08 (246) 0.415
Fasting plasma glucose (mmol/l) 6.360.7 (46) 6.160.7 (215) 6.160.8 (246) 0.653
2-h plasma glucose (mmol/l) 9.061.6 (46) 9.061.6 (215) 8.861.4 (246) 0.198
Fasting serum insulin (pmol/l) 16.568.7 (40) 14.566.5 (193) 14.767.9 (228) 0.574
2-h serum insulin (pmol/l) 105.4661.2 (39) 92.9657.3 (192) 95.9671.7 (227) 0.728
HOMA-IR (mmol6mU6l
22) 4.6162.43 (40) 4.0162.01 (193) 4.0962.47 (228) 0.550
HOMA-IS (U/mol) 126.8678.2 (40) 119.6673.2 (193) 115.7658.7 (228) 0.567
Total serum cholesterol (mmol/l) 5.8160.91 (46) 5.6460.96 (215) 5.5560.89 (245) 0.147
HDL cholesterol (mmol/l) 1.2560.32 (46) 1.2160.29 (215) 1.2060.29 (245) 0.523
LDL cholesterol (mmol/l) 3.6860.79 (45) 3.6460.86 (215) 3.5960.82 (244) 0.681
Triglycerides (mmol/l) 1.9560.92 (46) 1.7460.76 (215) 1.6860.75 (245) 0.139
Systolic blood pressure (mmHg) 138617 (45) 137.4617.8 (213) 139618 (244) 0.458
Diastolic blood pressure (mmHg) 8768 (45) 85610 (213) 86610 (244) 0.592
Values are means6SD; ANOVA for comparison among three genotype groups, adjusted for age, sex and BMI as main effects.
ap-value adjusted for age and sex.
bChi-square Test.
cKruskal-Wallis Test.
*FDR was .60% for all p-values.
doi:10.1371/journal.pone.0002941.t001
GHSR SNPs and Obesity
PLoS ONE | www.plosone.org 4 August 2008 | Volume 3 | Issue 8 | e2941affinity than to that of rs490683-C allele. At this position a putative
NF-1 binding site exists and is disrupted by the SNP rs490683,
changing the sequence from GCCA to CCCA. The NF-1 family of
site-specific DNA-binding proteins functions both as cellular TFs
in the regulation of gene expression and as replication factors for
adenovirus DNA replication [24]. Binding specificity of NF-1 is
equivalent to both the TGGCA-binding protein [25] and the
CAAT-box TF [26,27]. NF-1 protein binds as a dimer to the dyad
symmetric consensus sequence TTGGC(N5)GCCAA on duplex
DNA, although NF-1 can also bind specifically to individual half
sites (TTGGC or GCCAA) with somewhat reduced affinity [24].
NF-1 has been shown to activate transcription [24] and it can be
speculated that in individuals with rs490683-GG genotype, where
the NF-1 half site is intact, GHSR expression is enhanced, thus
potentially leading to an increase in receptor signalling and
ultimately to an increase in appetite [28]. In fact, our study shows
that subjects with rs490683-GG genotype lost less weight during a
lifestyle intervention than individuals with rs490683-CC genotype.
It has been shown recently that GHSR signals with ,50% activity
even inthe absence ofan agonist [29]. That impliesthat control ofthe
expression level of the receptor is directly correlated to signalling
activity [7]. It has been shown that during prolonged fasting, GHSR
expression in the hypothalamus is increased, which could contribute
to the amplification of ghrelin action [28] and could be expected to
result in a ghrelin-independent increase in receptor signalling and
thereby an increase in appetite [7]. The GHSR polymorphism
rs490683 was associated with weight change in our study population
and the rs4906863-GG genotype, where the NF-1 site is intact, might
lead to increased ghrelin receptor expression.
The alleles of rs519384 did not show differential protein
binding, indicating that the SNP is not in an important region for
GHSR gene expression. Although rs9819506 was associated with
weight and BMI, gelshift assays showed no difference in protein
binding between the alleles, which may be due to species
differences. Although we could observe a difference in protein
binding between the alleles of rs6772676, it cannot explain the
observed association with glucose levels.
TFs and more importantly their DNA binding domains are
highly conserved between humans and rodents. For example, the
nucleic acid sequence of the rat NF-1 is 99% identical to the
human sequence and on amino acid level there is a 91% overlap
between the sequences. The variations in the rat NF-1 protein
(compared to the human sequence) are not located within its DNA
binding domain, thus they are unlikely to affect its binding to
DNA. Due to the tissue unavailability from humans the rat protein
extract provides a good model to test for differential protein
binding to the alleles because of the high degree of conservation
between the two species. We used hypothalami of male rats only,
but obviously the autosomes of male and female rats are identical.
Only genes located on the Y-chromosome will differ between the
two sexes, whereas e.g. NF-1 is located on chromosome 17. Some
TFs might show a difference in their expression levels. Thus, the
gelshift bands might be stronger or weaker comparing males and
females but the clear difference of protein binding to the different
SNP alleles will still occur.
To our knowledge, no GWA study for obesity has been carried
out in Finns alone; however, samples from Finnish studies have
been used in replication studies (e.g. [18,19]). The primary GWA
studies investigating the genetics of type 2 diabetes are available.
The studies regarding type 2 diabetes in Finnish subjects
[20,21,30] have used the Illumina HumanHap300 Genotyping
BeadChips containing over 317,000 SNPs. Two SNPs in the
GHSR gene overlap with the SNPs investigated in our study, that is
rs9819506 and rs565105. One more SNP, rs10513702, is in high
LD (r
2=0.966) with rs6772676, which was also genotyped in our
study. Other GWA studies investigating obesity have used variably
the Affymetrix GeneChip Human Mapping 10K, 100K or 500K
Array Set [31,32,33,34]. In the 500K Array Set are 6 SNPs of the
GHSR gene included and one of those overlaps with the SNPs
genotyped in our study (rs509035). The other GHSR SNPs are not
in LD with SNPs which we genotyped. In GWA studies stringent
quality control criteria are applied for the given setting. Thus it is
possible that the few SNPs used in this study from the GHSR gene
did not match those criteria (e.g. call rate, Hardy-Weinberg
equilibrium for the given study population).
In summary, results of our study suggest that polymorphisms in
the GHSR gene are longitudinally associated with obesity and
glucose metabolism in a prospective study setting. Genetic
Figure 2. Weight and weight loss according to rs9819506 and
rs490683 genotypes in DPS. A. Weight according to rs9819506
genotypes in the entire study population. Mean6SEM are estimated
marginal means calculated from repeated measures ANOVA with sex
and age as significant covariates. rs9819506-GG (n=171, filled circles);
rs9819506-GA (n=200, open cirlces); rs9819506-AA (n=59, filled
triangles); pair-wise comparisons: GG vs. GA p=1.000, GG vs. AA
p=0.030, GA vs. AA p=0.116. B. Relative weight loss according to the
different genotypes of rs490683 in all subjects and separately in
intervention and control group. rs490683-CC (black bars); rs490683-CG
(striped bars); rs490683-GG (white bars). The q-value denotes the false
discovery rate (FDR) and is reported only for p,0.1. n.s., non-significant.
doi:10.1371/journal.pone.0002941.g002
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regulation by modulating gene expression of GHSR and
subsequently ghrelin receptor signalling. This study is the first to
show potential functional consequences of a GHSR SNP. Further
studies are warranted to confirm our results and to find SNPs that
are causal and have clinical relevance.
Figure 3. Glucose metabolism measures according to rs490683 genotypes in DPS. A. 2-h plasma glucose according to rs490683
genotypes in all subjects. Mean6SEM are estimated marginal means calculated from repeated measures ANOVA with group, age and BMI at baseline
as significant covariates. rs490683-CC (n=42, filled circles); rs490683-CG (n=171, open circles); rs490683-GG (n=210, filled triangles). Pair-wise
comparisons all subjects: CC vs. CG p=0.020, CC vs. GG p=0.295, CG vs. GG p=0.190. B–E. Relative changes fasting plasma glucose (B), 2-h plasma
glucose (C), fasting serum insulin (D) and 2-h serum insulin (E) according to the different genotypes of rs490683 in all subjects and separately in
intervention and control group. rs490683-CC (black bars); rs490683-CG (striped bars); rs490683-GG (white bars). The q-value denotes the false
discovery rate (FDR) and is reported only for p,0.1. n.s., non-significant.
doi:10.1371/journal.pone.0002941.g003
GHSR SNPs and Obesity
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Subjects and study design
The Finnish DPS is an intervention study carried out in five
centres in Finland (clinical trial reg. no: NCT00518167). The main
aim of the study was to assess the efficacy of an intensive
individually designed diet and exercise program to prevent or
delay the onset of type 2 diabetes in subjects with IGT. The study
design, subjects, inclusion and exclusion criteria and intervention
program have been described earlier in detail [35,36]. In brief,
522 overweight (BMI$25 kg/m
2) men and women aged 40 to 65
years with IGT participated in the study. DNA samples were
available from 507 individuals (intervention group 259 and control
group 248 subjects). IGT was defined as a 2-h plasma glucose
concentration of 7.8 to 11.0 mmol/l (oral glucose tolerance test
[OGTT] 75 g) with a fasting plasma glucose concentration less
than 7.8 mmol/l [37]. The persons enrolled in the study were
randomly assigned to one of the two treatment modalities, the
intervention group or the conventional care control group. The
study protocol was approved by the Ethics Committee of the
National Public Health Institute in Helsinki, Finland, and
conducted in accordance with the guidelines proposed in the
Declaration of Helsinki. All participants gave written informed
consent. We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human volunteers
were followed during this research.
Selection of GHSR SNPs and genotype analysis
For selection of GHSR SNPs for genotype analysis the HapMap
[38], NCBI [39] and Ensembl [40] databases were used.
Originally, six tag SNPs from two haploblocks covering 15 kb of
the gene including three SNPs in haploblock 1 in the 59 end of the
gene (rs474225, rs490683 (alternative name in HapMap
rs863441), rs9819506), and three SNPs in haploblock 2, one in
the coding region in exon 1 leading to a synonymous amino acid
substitution (rs495225), one in the intron (rs509035) and one in the
39 end of the GHSR gene (rs565105) were selected (Fig. 1A). In
addition, all SNPs in haploblock 1 in the 59 regulatory region
(spanning over 17 kb, chr 3: 173648897–17365897; NCBI
accession number for GHSR NM_198407.1) available in the
HapMap database and located in putative TF-binding sites were
tested for their functionality in gelshift experiments. SNPs which
showed different protein binding in vitro were genotyped
additionally (rs6772676).
Genotyping was performed with TaqMan Allelic Discrimina-
tion Assays (Applied Biosystems, Foster City, CA, USA). The PCR
amplification was performed in a GeneAmp PCR system 2700
(Applied Biosystems, Foster City, CA, USA) in following
conditions: 95uC for 10 min and 40 cycles of denaturation 92uC
for 15 sec and annealing/extension 60uC for 1 min. Allele-specific
fluorescence was detected on an ABI Prism 7000 sequence
detector. A subset of randomly selected samples representing 6.3%
of the study cohort was repeated.
Figure 4. Differential protein binding of rat hypothalamus nuclear protein extract. Gelshift experiments were performed with
32P-labeled
oligonucleotides containing one or the other allele of respective single nucleotide polymorphism (SNP). Numbers below the gels indicate the means
of three independent experiments with standard deviation (SD) in parenthesis. Protein binding of the ‘‘wild-type’’ allele was normalized to 100%.
Representative gels are shown. NS denotes non-specific DNA-protein interactions, which are not due to specific binding between the labelled DNA
and the proteins contained in the hypothalamus extract.
* p,0.05;
** p,0.001.
doi:10.1371/journal.pone.0002941.g004
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In silico promoter analysis of the sequences containing all SNPs
in haploblock 1 for putative TF-binding sites was performed using
Genomatix MatInspector Release professional 7.4.8.2 [22]. We
determined all SNPs that lie in possible TF-binding sites and
consequently all TF-binding sites that are disrupted by either one
of each SNP allele. We used a threshold of 0.75 for core similarity
and the optimized setting for matrix similarity.
Protein extraction
Hypothalami of three male Sprague-Dawley rats (supplier
Harlan, Netherlands) were pooled and the frozen tissue was
homogenized in 0.5 ml of low salt buffer (10 mM Hepes, pH 7.9,
1.5 mM MgCl2, 50 mM KCl, 0.5 mM dithiothreitol, proteinase
inhibitors) using a rotor-stator homogenizer (ART Labortechnik,
Mu ¨llheim, Germany). Cells were then resuspended in 2–3 packed
volumes of the same low salt buffer with 0.5% Nonidet P-40 and
homogenized by pipetting on ice. The nuclear pellet was
subsequently resuspended in one packed cell volume of high salt
buffer (10 mM Hepes, pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, protein-
ase inhibitors). Extraction was performed for 30 min on ice.
Gelshift assay
Gelshift assays were performed with 10 mg protein of the
nuclear extracts. The proteins were incubated for 15 min in a total
volume of 20 ml of binding buffer (150 mM KCl, 1 mM
dithiothreitol, 25 ng/ml herring sperm DNA, 5% glycerol,
10 mM Hepes, pH 7.9). Constant amounts (1 ng) of
32P-labeled
double-stranded oligonucleotides (50,000 cpm) containing either
one of the respective SNP alleles (supplementary Table S1) were
then added, and incubation was continued for 20 min at room
temperature. Protein-DNA complexes were resolved by electro-
phoresis in 8% non-denaturing polyacrylamide gels (mono- to
bisacrylamide ratio 19:1) in 0.56TBE (45 mM Tris, 45 mM boric
acid, 1 mM EDTA, pH 8.3) for 90 min at 200 V and quantified
on a FLA-3000 reader (Fuji, Tokyo, Japan) using ScienceLab99
software (Fuji).
Statistical analysis
The significances of differences in genotype and allele
frequencies were analyzed using a chi-square test and a two-sided
Fisher’s exact test, respectively. Normal distributions were tested
with the Kolmogorov-Smirnov test with Lilliefors correction. To
normalize the skewed distributions, logarithmic transformations or
reciprocal transformations were applied when needed. The
differences in continuous variables between genotypes of single
SNPs at baseline were evaluated with the general linear model
(GLM) for the univariate analysis of variance (ANOVA).
Biochemical measurements were adjusted for age, sex and BMI
as main effects and weight-related variables for age and sex only.
When variables could not be transformed to be normally
distributed, Kruskal-Wallis test was used. GLM repeated measures
ANOVA was used to analyze differences between genotypes of
each SNP during the follow-up period concerning obesity-related
and insulin- and glucose-metabolism related phenotypes. A final
model was built manually with a backward selection procedure
with following covariates included: age at baseline, sex, study
group and BMI at baseline, as appropriate. Genotype*group
interaction was tested and groups were analyzed separately if the
Table 2. Single nucleotide polymorphisms (SNPs) in the GHSR promoter and putative transcription factor (TF) binding sites.
SNP Allele Putative TF binding sites
rs6772676
1,2 C Activating transcription factor, ATF-1
Pax-3 paired domain protein, expressed in embryogenesis, mutations correlate to Waardenburg Syndrome
T PBX - HOXA9 binding site
rs9881097 T Avian C-type LTR TATA box
C Pu.1 (Pu120) Ets-like TF identified in lymphoid B-cells
PAX 2/5/8 binding site
rs474225
1 T Fkh-domain factor FKHRL1 (FOXO)
Interferon regulatory factor 3 (IRF-3)
C-
rs490683
1,2 C Orphan nuclear receptor rev-erb alpha (NR1D1), monomer binding site
G Non-palindromic nuclear factor I binding sites
rs11918879 C Brn-5, POU-VI protein class (also known as emb and CNS-1)
T Brn-5, POU-VI protein class (also known as emb and CNS-1)
rs477441 A Hepatic nuclear factor 1
C Ecotropic viral integration site 1 encoded factor, amino-terminal zinc finger domain
rs9819506
1 G TEA domain-containing factors, transcriptional enhancer factors 1,3,4,5
Octamer binding site (OCT1/OCT2)
Octamer-binding factor 1, POU-specific domain
A-
rs519384 A Liver enriched Cut - Homeodomain TF HNF6 (ONECUT)
T Liver enriched Cut - Homeodomain TF HNF6 (ONECUT)
1SNPs genotyped from DPS population.
2different protein binding in gelshift assay.
doi:10.1371/journal.pone.0002941.t002
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between all three genotype groups and pairwise comparisons
based on estimated marginal means were adjusted for multiple
comparisons with Bonferroni correction. Relative changes in
weight and measures of glucose and insulin metabolism from
baseline to year 3 were analyzed with Kruskal-Wallis test, because
data were not normally distributed even after applying several
transformations. A p-value of 0.05 or lower was considered
statistically significant. Correction for multiple hypothesis testing
was performed with FDR using the Q-value 1.0 software [41]. p0
was estimated with bootstrap method using a l range from 0 to 0.9
by 0.05. The FDR for each p-value is reported as q-value. The q-
value threshold is the proportion of significant features that turn
out to be false leads. Data are given as means6SD, unless
otherwise stated. All data were analyzed using SPSS for Windows
14.0 (SPSS Inc., Chicago, IL, USA). LD statistics were calculated
and haplotype blocks were visualized by using the Haploview
software [42].
Supporting Information
Table S1 Oligonucleotides used in gelshift assays. List of
oligonucleotides which were used to test the difference in protein
binding among different GHSR SNP alleles.
Found at: doi:10.1371/journal.pone.0002941.s001 (0.04 MB
DOC)
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